Uterine Corpus Carcinoma
📧 Sign up to get email alerts when something new happens for Uterine Corpus Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers [Phase 1]
This is a Phase 1 clinical trial update evaluating the combination of APG-1252 (Pelcitoclax) and cobimetinib in recurrent and advanced ovari…
-
CLINICAL_TRIALS trial_result · 2025-09-23Clinical Trial Update: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone [Phase 2]
Phase 2 trial in recurrent or refractory endometrial cancer evaluating Olaparib with Durvalumab, Cediranib with Durvalumab, Olaparib with Ca…
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer [Phase 2]
Phase 2 trial evaluating enzalutamide in combination with carboplatin and paclitaxel for stage III-IV or recurrent endometrioid endometrial …
-
CLINICAL_TRIALS trial_result · 2020-02-17Clinical Trial Update: Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer [Phase 2]
Phase 2 trial evaluating sunitinib malate in patients with recurrent or metastatic endometrial cancer has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer [Phase 2]
Phase 2 trial investigating gefitinib for recurrent endometrial cancer (uterine corpus carcinoma) has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-02-27Clinical Trial Update: Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer [Phase 2]
Phase 2 trial evaluating three regimens for endometrial cancer: paclitaxel-carboplatin-bevacizumab, paclitaxel-carboplatin-temsirolimus, and…
-
CLINICAL_TRIALS trial_result · 2017-12-05Clinical Trial Update: Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]
Phase 2 trial evaluating gemcitabine in patients with recurrent or persistent endometrial cancer completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-11-29Clinical Trial Update: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer [Phase 2]
Phase 2 clinical trial of trebananib for persistent or recurrent endometrial cancer has completed, with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-09-05Clinical Trial Update: Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer [Phase 2]
Phase 2 trial evaluating MK2206, an Akt inhibitor, in recurrent or advanced endometrial cancer; study completed with results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-08-28Clinical Trial Update: Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]
Phase 2 clinical trial evaluating cediranib maleate for recurrent or persistent endometrial cancer has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2014-01-20Clinical Trial Update: Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer [Phase 2]
Phase 2 trial of selumetinib in recurrent or persistent endometrial cancer has completed with results posted in 2014.